SLFN11 and cancer: Such optimized derivatives could then be applied in cancer therapy as potential adjuvants in combination with DNA damaging agents, especially to treat those tumors characterized by overexpression of SLFN-11 making them more sensitive to DNA damage as previously proven by several studies and also shown in this study by the potentiation of the cytotoxic effect of temozolomide (TMZ) towards the highly SLFN-11 expressing cell line MDA-MB-468 upon addition of the bioavailable hPARP-1 inhibitor olaparib (OLP).